Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should FDA Warning Letter Prompt Securities Suit? Government, PhRMA Disagree

This article was originally published in The Pink Sheet Daily

Executive Summary

Supreme Court is to decide when Merck investors had sufficient information to sue for securities fraud; FDA warning letter about Vioxx risks is at issue.
Advertisement

Related Content

Supreme Court Lets Vioxx Securities Suit Against Merck Stand
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
Vioxx's Long Shadow: Supreme Court Skeptical Of Merck's Argument On Timing Of Securities Suits
Vioxx's Long Shadow: Supreme Court Skeptical Of Merck's Argument On Timing Of Securities Suits
Must Sponsors Announce All Adverse Events To Avoid Securities Lawsuits?
Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case
Must Sponsors Announce All Adverse Events To Avoid Securities Lawsuits?
Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case
Appeals Court Reinstates Vioxx Securities Class Action Against Merck
Appeals Court Reinstates Vioxx Securities Class Action Against Merck

Topics

Advertisement
UsernamePublicRestriction

Register

PS068665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel